Health-Related Quality of Life in a National Cohort of Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension;Calidad de vida relacionada con la salud en una cohorte nacional de pacientes con hipertensión arterial pulmonar o hipertensión pulmonar tromboembólica crónica

Archivos de Bronconeumologia

Volumn 49, Issue 5, 2013, Pages 181-188

  Roman, Antonio ^a   Barbera, Joan Albert ^b   Castillo, Maria Jesús ^c   Muñoz, Rocío ^d   Escribano, Pilar ^e  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d PFIZER INC   (United States)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Chronic thromboembolic pulmonary hypertension; EuroQol 5D questionnaire; Health related quality of life; Pulmonary arterial hypertension; Short Form SF 36 questionnaire

Indexed keywords

ADULT; ARTICLE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; COHORT ANALYSIS; EUROQOL 5D; FEMALE; FUNCTIONAL STATUS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; QUALITY OF LIFE; SHORT FORM 36; VISUAL ANALOG SCALE;

EID: 84876844447     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2012.12.002     Document Type: Article

References (26)

1. Gaine S.P., Rubin L.J. Primary pulmonary hypertension. Lancet 1998, 352:719-725.
2. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
3. Macchia A., Marchioli R., Tognoni G., Scarano M., Marfisi R., Tavazzi L., et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J 2010, 159:245-257.
4. Galiè N., Manes A., Negro L., Palazzini M., Bacchi-Reggiani M.L., Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009, 30:394-403.
5. Wilson I.B., Cleary P.D. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995, 273:59-65.
6. Chen H., Taichman D.B., Doyle R.L. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc 2008, 5:623-630.
7. Hoeper M.M., Oudiz R.J., Peacock A., Tapson V.F., Haworth S.G., Frost A.E., et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004, 43(12 Suppl S):48S-55S.
8. Condliffe R., Kiely D.G., Gibbs J.S., Corris P.A., Peacock A.J., Jenkins D.P., et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008, 177:1122-1127.
9. Chen Y.F., Jowett S., Barton P., Malottki K., Hyde C., Gibbs J.S., et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess 2009, 13:1-320.
10. Pepke-Zaba J., Gilbert C., Collings L., Brown M.C. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest 2008, 133:183-189.
11. McKenna S.P., Doughty N., Meads D.M., Doward L.C., Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006, 15:103-115.
12. Shafazand S., Goldstein M.K., Doyle R.L., Hlatky M.A., Gould M.K. Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004, 126:1452-1459.
13. Cenedese E., Speich R., Dorschner L., Ulrich S., Maggiorini M., Jenni R., et al. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 2006, 28:808-815.
14. Yoshimi S., Tanabe N., Masuda M., Sakao S., Uruma T., Shimizu H., et al. Survival and quality of life for patients with peripheral type chronic thromboembolic pulmonary hypertension. Circ J 2008, 72:958-965.
15. Alonso J., Regidor E., Barrio G., Prieto L., Rodríguez C., de la Fuente L. Population reference values of the Spanish version of the Health Questionnaire SF-36. Med Clin (Barc) 1998, 111:410-416.
16. Keogh A.M., McNeil K.D., Wlodarczyk J., Gabbay E., Williams T.J. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant 2007, 26:181-187.
17. Simonneau G., Rubin L.J., Galiè N., Barst R.J., Fleming T.R., Frost A.E., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149:521-530.
18. Galiè N., Rubin L., Hoeper M., Jansa P., Al-Hiti H., Meyer G., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008, 371:2093-2100.
19. Galiè N., Brundage B.H., Ghofrani H.A., Oudiz R.J., Simonneau G., Safdar Z., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903.
20. Gilbert C., Brown M.C., Cappelleri J.C., Carlsson M., McKenna S.P. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 2009, 135:137-142.
21. Taichman D.B., Shin J., Hud L., Archer-Chicko C., Kaplan S., Sager J.S., et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005, 6:92.
22. Zlupko M., Harhay M.O., Gallop R., Shin J., Archer-Chicko C., Patel R., et al. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med 2008, 102:1431-1438.
23. Denton C.P., Pope J.E., Peter H.H., Gabrielli A., Boonstra A., van den Hoogen F.H., et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 2008, 67:1222-1228.
24. Strange G., Keogh A.M., Williams T.J., Wlodarczyk J., McNeil K.D., Gabbay E. Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6minute walk distance and quality of life. Respirology 2008, 13:674-682.
25. Humbert M., Sitbon O., Yaïci A., Montani D., O'Callaghan D.S., Jaïs X., et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010, 36:549-555.
26. Mathai S.C., Puhan M.A., Lam D., Wise R.A. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2012, 186:428-433.